Clinical Trials

View on ClinicalTrials.gov
Development Highlights
1. Targeting Liver–Adipose Signaling
An investigational siRNA designed to silence hepatic INHBE expression and reduce Activin E production, modulating liver–adipose signaling to explore a non-incretin approach to obesity treatment.
2. Potential to Improve Body Composition
Supported by human genetic evidence and preclinical findings, MWN117 is being investigated for its potential to reduce visceral fat and improve body composition.
3. Potential Beyond Obesity: Relevance to MASH
By targeting liver–adipose signaling, MWN117 may offer opportunities for future investigation in metabolic dysfunction–associated steatohepatitis (MASH), with a focus on hepatic fat accumulation and related metabolic dysfunction.
For licensing and partnership inquiries, please contact us (bd@lepu-medical.com).
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
